---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-24-004601"
form_type: "8-K"
ticker: "SBFM"
cik: "0001402328"
company_name: "Sunshine Biopharma Inc."
filed_at: "2024-07-02T23:59:59+00:00"
generated_at: "2026-05-31T23:44:30.646423+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Majority shareholder approves up to 60-for-1 reverse stock split

## Summary
- Dr. Steve Slilaty, holding 84.8% voting power, approved reverse split by written consent.
- Reverse split ratio up to 60-for-1 of common stock.
- Effective 20 days after mailing definitive information statement to shareholders.
- Dr. Slilaty is CEO and controls majority voting power.

## SEC filing metadata
- accession: 0001683168-24-004601
- form_type: 8-K
- ticker: SBFM
- cik: 0001402328
- company_name: Sunshine Biopharma Inc.
- filed_at: 2024-07-02T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1402328/000168316824004601/0001683168-24-004601-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1402328/000168316824004601/sunshine_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-24-004601
- JSON: https://secwatch.observer/filing/0001683168-24-004601.json
- Plain text: https://secwatch.observer/filing/0001683168-24-004601.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.